LHDX - Lucira gets EU clearance to sell both COVID-19 & flu and COVID-19 molecular tests

Lucira Health (NASDAQ:LHDX) on Monday said both its COVID-19 & flu and COVID-19 molecular tests have been cleared for sale and distribution throughout the European Union. Both tests developed by the company run on a palm-sized device with no separate instrument or reader and produce results in 30 minutes, Lucira said. LHDX's COVID-19 test is currently available in the U.S., Canada, Singapore, Israel, and Taiwan. LHDX stock closed -9.7% at $2.78 on Friday.

For further details see:

Lucira gets EU clearance to sell both COVID-19 & flu and COVID-19 molecular tests